September Drug Recalls
This article was originally published in The Gold Sheet
You may also be interested in...
Economically motivated adulteration, glass flakes in vials, out-of-specification transdermal patches, malodorous bottles and prefilled syringe sterility were among the more significant manufacturing quality issues leading to drug recalls in the past three months.
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.